ArticleInternational journal of colorectal disease2024

Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.

Kota Ouchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.